Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2399-3669

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model ; volume:2 ; number:1 ; day:22 ; month:3 ; year:2019 ; pages:1-14 ; date:12.2019
Communications chemistry ; 2, Heft 1 (22.3.2019), 1-14, 12.2019

Creator: Dighe, Satish N.
De la Mora, Eugenio
Chan, Stephen
Kantham, Srinivas
McColl, Gawain
Miles, Jared A.
Veliyath, Suresh Kumar
Sreenivas, B. Yogi
Nassar, Zeyad D.
Silman, Israel
Sussman, Joel L.
Weik, Martin
McGeary, Ross P.
Parat, Marie-Odile
Brazzolotto, Xavier
Ross, Benjamin P.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s42004-019-0133-4

URN: urn:nbn:de:101:1-2019041101081194325889

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Dighe, Satish N.
De la Mora, Eugenio
Chan, Stephen
Kantham, Srinivas
McColl, Gawain
Miles, Jared A.
Veliyath, Suresh Kumar
Sreenivas, B. Yogi
Nassar, Zeyad D.
Silman, Israel
Sussman, Joel L.
Weik, Martin
McGeary, Ross P.
Parat, Marie-Odile
Brazzolotto, Xavier
Ross, Benjamin P.
SpringerLink (Online service)

Other Objects (12)

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Related objects

Reset password